Gilead Sciences Inc. (GILD)
NASDAQ: GILDHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
GILD stock chart
Technical analysisKey statistics
All statistics- Market cap
- $206.43B
- Forward P/E
- 16.40
- EPS (TTM)
- -$3.13
- Dividend yield
- 1.95% ($3.25)
- Ex-dividend date
- Dec 15, 2026
- 52-week range
- 116.88 – 176.58
- Day range
- 165.80 – 170.24
- Volume / Avg
- 7.56M / 5.98M
- Beta
- —
- Shares outstanding
- 1.24B
52-week range
GILD stock today
Gilead Sciences (GILD) closed at $166.43 on Nov 20, down 0.06% (-$0.10), versus the S&P 500's 3.70% decline. At this level, GILD sits near the top of its 52-week range of $116.88 to $176.58: 5.7% below the high, set on Nov 5, 2026 and 42.4% above the low. GILD is up 35.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 31.4%.
Gilead Sciences has posted a net loss over the last twelve months (EPS of -$3.13), so its P/E ratio is not meaningful. Gilead Sciences pays an annual dividend of $3.25 per share, a 1.95% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Gilead Sciences
Company profileGilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Daniel Patrick O'Day
- Headquarters
- Foster City, CA
- Employees
- 17,000
- IPO year
- 1992
- Website
- gilead.com
Financial highlights
Full financialsIn fiscal 2025, Gilead Sciences generated $29.44 billion in revenue, up 2.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Net income was $8.51 billion (+1672.9% year over year), for a net margin of 28.9% versus a median of 16.8% in the prior 5 years. Gross margin was 78.8% (up from 78.3%) and operating margin 34.0%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $29.44B | $28.75B | $27.12B | $27.28B | $27.30B |
| Growth | +2.40% | +6.04% | -0.60% | -0.09% | +10.60% |
| Net income | $8.51B | $480.00M | $5.67B | $4.59B | $6.22B |
| EPS (diluted) | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 |
Analyst forecast
ForecastConsensus (28 analysts)
buy
Avg. price target
$175.92+5.70%
- Strong buy 6
- Buy 16
- Hold 5
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $2.47 vs $2.17
- Surprise
- +13.82%
Dividends
Dividend history- Annual dividend
- $3.25
- Dividend yield
- 1.95%
- Last payment
- $0.82
- Ex-dividend date
- Dec 15, 2026
- Pay date
- Dec 30, 2026
GILD news
All GILD news- Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should KnowNasdaq
- Gilead Sciences, Inc. (GILD) Presents at Jefferies Global Healthcare Conference 2026 TranscriptSeeking Alpha
- Gilead Sciences, Inc. (GILD) Presents at UBS Global Biopharma Conference 2026 TranscriptSeeking Alpha
- Gilead Sciences Maps Growth Beyond BIKTARVY With HIV, Cancer and Inflammation DrugsNasdaq
- J&J to Acquire Ollin Biosciences: A Look at Its Recent BuyoutsNasdaqJNJ, LLY, GILD, ABBV
- Gilead Sciences Bets on HIV Prevention Growth Despite $1.5 Billion Biktarvy HeadwindNasdaq
- Gilead Broadens Ebola Strategy With Obeldesivir Licensing Deals, Remdesivir Agreement ExpansionNasdaq
- Gilead: Growth Supports A Hold Despite A Valuation PremiumSeeking Alpha
Gilead Sciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMGNAmgen Inc. | 435.64 | -0.15% | $235.64B | vs GILD |
| MRNAModerna Inc. | 195.00 | -2.17% | $78.90B | vs GILD |
| ARGXargenx SE ADR | 925.70 | -1.73% | $58.21B | vs GILD |
| BIIBBiogen Inc. | 249.59 | +1.00% | $36.89B | vs GILD |
| RVMDRevolution Medicines Inc. | 161.20 | +1.11% | $34.87B | vs GILD |
| BNTXBioNTech SE ADR | 80.96 | -0.52% | $20.07B | vs GILD |
| EXELExelixis Inc. | 64.63 | -1.82% | $15.77B | vs GILD |
| NBIXNeurocrine Biosciences Inc. | 150.57 | -3.84% | $15.24B | vs GILD |
Indexes, lists and sector
Index membership
Appears in lists
Gilead Sciences stock FAQ
What is Gilead Sciences's stock price today?
GILD last traded at $166.43 as of Nov 20, 4:00 PM EST, down 0.06% on the day. Prices are delayed at least 15 minutes.
Does Gilead Sciences pay a dividend?
Yes. Gilead Sciences pays $3.25 per share annually, a 1.95% yield. The most recent dividend of $0.82 had an ex-dividend date of Dec 15, 2026.
Is Gilead Sciences in the S&P 500?
Yes. Gilead Sciences (GILD) is a constituent of the S&P 500 index.
Who is Gilead Sciences's CEO?
Mr. Daniel Patrick O'Day is the chief executive officer of Gilead Sciences Inc., which has about 17,000 employees.
Has GILD ever split its stock?
Yes. The most recent GILD stock split was a 2-for-1 split on Jan 28, 2013, one of 5 splits on record.
What is the GILD 52-week high?
The 52-week high for GILD is $176.58 and the 52-week low is $116.88. The stock is currently 5.7% below its high.